抗体来源(Source)
Cynomolgus IgG1 Kappa Isotype Control (mAb) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Cynomolgus constant domain.
亚型(Isotype)
Cynomolgus IgG1 | Cynomolgus Kappa
偶联(Conjugate)
Unconjugated
抗体类型(Antibody Type)
Recombinant Monoclonal
种属反应性(Reactivity)
Cynomolgus
特异性(Specificity)
This product is a specific antibody specifically reacts with DNP.
应用(Application)
Application | Recommended Usage |
ELISA | 1-5000 ng/mL |
纯度(Purity)
>90% as determined by SDS-PAGE.
纯化(Purification)
Protein A purified / Protein G purified
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
电泳(SDS-PAGE)
Cynomolgus IgG1 Kappa Isotype Control (mAb) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
活性(Bioactivity)-ELISA
Immobilized DNP-Albumin Conjugate, Bovine at 10 μg/mL (100 μL/well) can bind Cynomolgus IgG1 Kappa Isotype Control (mAb) (Cat. No. DNP-M553) with a linear range of 0.001-0.25 μg/mL (QC tested).
Protocol
背景(Background)
A hapten is a small molecule that can elicit an immune response only when conjugated with a large carrier such as a protein. Typical haptens include drugs, urushiol, quinone, steroids, etc. Peptides and non-protein antigens usually need conjugating to a carrier protein (such as BSA (bovine serum albumin) or KLH (keyhole limpet hemocyanin) to become good immunogens). Additionally, haptens should be administered with an adjuvant to ensure a high quality immune response. It is important that the hapten design (preserving greatly the chemical structure and spatial conformation of target compound), selection of the appropriate carrier protein and the conjugation method are key conditions for the desired specificity anti-hapten antibodies. We design anti-hapten antibodies based on the HaptenDB information.